Moringa Oleifera leaf extract reduces inflammation status of breast cancer patients with estrogen receptor (+) and estrogen receptor (+) receiving Aromatase Inhibitor Therapy Cancer
Conditions
Interventions
The research sample was divided into 2 groups: control and treatment groups.
The treatment group received a 300 mg capsule of Moringa leaf extract with a daily dose of 600 mg and dicl
Sponsors
Diponegoro University
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: 1. Breast cancer patient 2. Post menopause 3. Imunohistokimia Estrogen receptor (+), Progesteron receptor (+) 4. Received aromatase inhibitor 5. Patient with Aromatase Inhibitor-Associated Musculoskeletal Syndrome
Exclusion criteria
Exclusion criteria: 1. Emergency condition that needs operation 2. Visceral metastasis 3. History of previous degenerative joint and soft tissue disease (osteoarthritis/rheumatoid arthritis). 4. History of fracture during the last 6 months
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Inflammation status is measured using data on the levels of ESR, CRP, CPK, and ANA. Data is gathered pre-treatment and after treatment (30 days) | — |
Secondary
| Measure | Time frame |
|---|---|
| Measured using blood test: 1. Erythrocyte Sedimentation rate (ESR) measured at pre-treatment and after treatment (30 days) 2. C-Reactive Protein (CRP) measured at pre-treatment and after treatment (30 days) 3. Anti-Nuclear Antibody (ANA) measured at pre-treatment and after treatment (30 days) 4. Creatine Phosphokinase (CPK) measured at pre-treatment and after treatment (30 days) | — |
Countries
Indonesia
Contacts
Public ContactYan wisnu Prajoko
Outcome results
None listed